All articles tagged with #johnson and johnson
Johnson & Johnson is expanding its operations in Wilson, North Carolina, with a multibillion-dollar investment to build a new factory that will produce cancer drugs, creating hundreds of new jobs. The state is supporting this growth with a $12 million program to train workers, highlighting North Carolina's appeal for life sciences companies and its focus on workforce development.
Johnson & Johnson has reached an agreement with the US government to lower drug prices for Americans in exchange for tariff exemptions, participating in initiatives to make medicines more affordable and building new manufacturing facilities in the US as part of a broader investment plan.
Johnson & Johnson has reached an agreement with the U.S. government to lower drug prices for Americans in exchange for tariff exemptions, participating in discounted drug sales and expanding manufacturing investments in the U.S.
Johnson & Johnson has reached a voluntary agreement with the U.S. government to improve access to medicines and lower costs for Americans, including discounts and tariff exemptions, while also investing $55 billion in U.S. manufacturing and research, with new facilities announced in North Carolina and Pennsylvania.
Johnson & Johnson has completed its $3.05 billion acquisition of Halda Therapeutics, a biotech company with a novel RIPTAC platform for developing targeted oral therapies for solid tumors, including prostate cancer, aiming to revolutionize cancer treatment and expand its oncology portfolio.
Johnson & Johnson has discontinued its experimental eczema medication after it failed to meet efficacy standards, ending its $1.25 billion investment in the drug.
Johnson & Johnson has discontinued its mid-stage trial of the experimental eczema drug JNJ-5939 after it failed to meet efficacy goals, but remains committed to developing other treatments for atopic dermatitis.
Johnson & Johnson announced that their Phase 2b DUPLEX-AD study for JNJ-5939 in treating moderate to severe atopic dermatitis was terminated early after not meeting efficacy criteria, though the drug was well tolerated. The company remains committed to developing new treatments for the high-need condition.
A Baltimore jury awarded over $1.5 billion to Cherie Craft, who claimed J&J's talc products caused her asbestos-related cancer, and J&J plans to appeal, citing the verdict as egregious and unconstitutional. The case adds to thousands of lawsuits against J&J over talc-related health claims, which the company denies, asserting its products are safe.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum powder exposed her to asbestos and contributed to her developing mesothelioma, part of ongoing legal battles over the safety of talc products.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum powder, contaminated with asbestos, caused her mesothelioma, highlighting ongoing legal battles over the safety of talc products.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum products caused her asbestos-related cancer, marking a significant legal victory amid ongoing lawsuits alleging health risks from talc. Johnson & Johnson plans to appeal the verdict, which is part of a broader legal battle over the safety of their talc products.
A Los Angeles jury awarded $40 million to two women claiming Johnson & Johnson's talcum powder caused their ovarian cancer, amid ongoing legal battles over the safety of talc in their products. Johnson & Johnson plans to appeal the verdict, which follows other recent large settlements related to talc and cancer claims.
Texas' attorney general sued Tylenol's makers, alleging deceptive marketing and knowing about a potential link between acetaminophen and autism, amid ongoing debates and legal battles over the safety of the painkiller during pregnancy.
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging they concealed the potential link between Tylenol (acetaminophen) and autism/ADHD, despite government confirmation of risks and public warnings by Trump. Kenvue defends Tylenol's safety, while Johnson & Johnson disclaims liability, leading to stock declines for both companies.